Table 2.
Characteristics | Placebo (n = 15) | Methylprednisolone (n = 15) | p value |
---|---|---|---|
Intraoperative data | |||
Duration of procedure (min) | 189 ± 43 | 204 ± 58 | 0.43 |
Duration of CPB (min) | 99.4 ± 25 | 115 ± 31 | 0.14 |
Duration of aortic cross-clamping (min) | 81.5 ± 25 | 91.7 ± 29 | 0.28 |
Intra-operative dose of phenylephrine (mg) | 1.02 ± 1.1 | 1.36 ± 1.0 | 0.39 |
Intra-operative dose of norepinephrine (mg) | 0.58 ± 1.3 | 0.56 ± 0.55 | 0.95 |
Plasma glucose levels | 0.096 | ||
Start of procedure (mmol/l) | 6.34 ± 1.5 | 5.25 ± 0.47 | |
During CPB (mean), (mmol/l) | 6.52 ± 0.94 | 7.25 ± 1.0 | |
After CPB (mmol/l) | 7.15 ± 0.97 | 8.50 ± 1.7 | |
Arrival ICU (mmol/l) | 6.20 ± 0.5 | 7.20 ± 1.6 | |
Day 1 ICU (mmol/l) | 6.27 ± 1.2 | 6.44 ± 1.2 | |
Insulin demand U/hour (intraoperatively + ICU) | 1.14 ± 0.74 | 2.46 ± 1.27 | 0.009 |
Postoperative data | |||
Serum creatinine (μmol/l) | 83.9 ± 18 | 94.9 ± 21 | 0.14 |
Vasopressor treatment, n | 6 | 9 | 0.47 |
Inotropic treatment (n) | 0 | 0 | 1.0 |
Reoperation for bleeding (n) | 0 | 0 | 1.0 |
ICU readmission (n) | 0 | 1 | 1.0 |
Atrial fibrillation/flutter, (n) | 5 | 10 | 0.14 |
Neurological complication, (n) | 2 | 1 | 1.0 |
Pneumonia, (n) | 0 | 1 | 1.0 |
Wound infection, (n) | 1 | 1 | 1.0 |
Other infection, (n) | 0 | 2 | 0.48 |
Length of stay in ICU (hours) | 24.8 ± 14 | 22.7 ± 12 | 0.65 |
Values are mean ± SD. CPB cardiopulmonary bypass, ICU intensive care unit. **p < 0.01